抗凋亡抑制剂维奈克拉在治疗髓系白血病的研究进展

doi:10.16352/j.issn.1001-6325.2023.05.0833

基础医学与临床 ›› 2023, Vol. 43 ›› Issue (5): 833-836.doi: 10.16352/j.issn.1001-6325.2023.05.0833

抗凋亡抑制剂维奈克拉在治疗髓系白血病的研究进展

向彩霞¹, 黄彬涛^1*, 郝建²

内蒙古医科大学附属医院 1.血液科;2.肾内科;内蒙古呼和浩特 010059

收稿日期:2022-03-14 修回日期:2022-11-16 出版日期:2023-05-05 发布日期:2023-04-26
通讯作者: ^*huangbintao1979@sina.com
基金资助:
内蒙古自然科学基金(2019MS08028);内蒙古医科大学校级面上项目(YKD2022MS014)

Research progress of anti-apoptotic inhibitor venetoclax in treatment of myeloid leukemia

XIANG Caixia¹, HUANG Bintao^1*, HAO Jian²

1. Department of Hematology; 2. Department of Nephrology,the Affiliated Hospital of Inner Mongolia Medical University, Hohhot 010059, China

Received:2022-03-14 Revised:2022-11-16 Online:2023-05-05 Published:2023-04-26
Contact: ^*huangbintao1979@sina.com

摘要/Abstract

摘要： 抗凋亡蛋白Bcl-2抑制剂维奈克拉(Ven)能够显著改善不适合强化化疗的老年以及复发/难治的急性髓系白血病(AML)患者的缓解率和远期生存。临床治疗中伴随出现TP53/FLT3突变、异常脂肪酸及氨基酸的能量代谢、Mcl-1蛋白的高表达以及铁死亡程序的激活等多种机制,参与了Ven耐药发生和白血病进展。深入探索导致Ven治疗髓系白血病耐药的机制,有助于克制Ven耐药产生和持续改善白血病患者的远期生存。

关键词: 急性髓系白血病, 维奈克拉(Ven), 凋亡, 铁死亡

Abstract: The anti-apoptotic protein Bcl-2 inhibitor venetoclax (Ven) can significantly improve the remission rate and long-term survival of elderly and relapsed/refractory acute myeloid leukemia(AML) patients who are not sensitive to intensive chemotherapy. TP53/FLT3 mutation, abnormal energy metabolism of fatty acids and amino acids, high expression of Mcl-1 protein and activation of ferroptosis program occur during clinical treatment are all involved in the development of Ven resistance and leukemia progression. Further exploration of the mechanisms leading to Ven resistance in myeloid leukemia may help to inhibit the development of Ven resistance and continuously improve the long-term survival of leukemia patients.

Key words: acute myeloid leukemia, venetoclax(Ven), apoptosis, ferroptosis

中图分类号:

向彩霞, 黄彬涛, 郝建. 抗凋亡抑制剂维奈克拉在治疗髓系白血病的研究进展[J]. 基础医学与临床, 2023, 43(5): 833-836.

XIANG Caixia, HUANG Bintao, HAO Jian. Research progress of anti-apoptotic inhibitor venetoclax in treatment of myeloid leukemia[J]. Basic & Clinical Medicine, 2023, 43(5): 833-836.

参考文献

[1]Roldán Pérez A,Vázquez Paganini JA, Penalva Moreno MJ,et al. Real-life experience of venetoclax and hypomethylating agents in acute myeloid leukemia patients not candidates for intensive chemotherapy or who are refrac-tory/relapsed: a single-centre experience[J].Clin Case Rep,2022:6116-6130.
[2]Pei S,Pollyea DA,Gustafson A,et al.Monocyticsubclonesconferresistance to venetoclax-based therapy in patients with acute myeloid leukemia[J]. Cancer Discov, 2020,536-551.
[3]Richter A,Lange S,Holz C, et al. Effective tumor cell abrogation via venetoclax-mediated BCL-2 inhibitionin KMT2A-rearrange dacute B-lymphoblastic leukemia[J].Cell Death Discov,2022,1:302-313.
[4]Janotka Ł, Messingerová L,Šimoničová K,et al. Changes in apoptotic pathwaysin MOLM-13 cell lines after induction of resistance to hypomethylating agents[J].Int J Mol Sci, 2021, 19:2076-3000.
[5]Cojocari D, Smith BN, Purkal JJ,et al.pevonedistat and azacitidine upregulate NOXA (PMAIP1)toincrease sensitivity to venetoclax in preclinical models of acute myeloid leukemia[J].Haematologica, 2022,1:825-835.
[6]DiNardo CD, Pratz KW, Letai A, et al. Safety and preliminary efficacy of venetoclax with decitabine or azacitidine in elderly patients with previously untreated acute myeloid leukaemia: a non-randomised, open-label, phase 1b study[J].Lancet Oncol, 2018: 216-228.
[7]于文静,贾晋松,王婧,等.维奈克拉联合阿扎胞苷治疗急性髓系白血病的近期疗效:单中心数据[J]. 中华血液学杂志,2022:134-140.
[8]王鹏,张露巍,陆棽琦,等.维奈克拉联合阿扎胞苷与地西他滨联合预激方案治疗老年复发急性髓系白血病的疗效及安全性比较的初步观察[J].中华内科杂志,2022,157-163.
[9]苏鹏忠,何家驩,于姗,等. Met-tRNAi~(Met)载体蛋白在急性髓系白血病(AML)中的表达及功能[J].基础医学与临床,2021:501-507.
[10]DiNardo CD,TiongI S,Quaglieri A et al. Molecular patterns of response and treatment failure after frontline venetoclax combinations in older patients with AML[J]Blood,2020,12,791-803.
[11]Zhang Q,Riley-Gillis B,Han L,et al.Activation of RAS/MAPK pathway confers MCL-1 mediated acquired resistance to BCL-2 inhibitor venetoclaxin acute myeloid leukemia[J].Signal Transduct Target Ther,2022:51-64.
[12]Jones CL,Stevens BM,Pollyea DA,et al.Nicotinamide metabolism mediates resistance to venetoclax in relapsed acute myeloid leukemia stem cells[J].Cell Stem Cell,2020,5:748-764.
[13]Stevens BM,Jones CL,Pollyea DA,et al. Fatty acid metabolism underlies venetoclax resistance in acute myeloid leukemia stem cells[J]. Nat Cancer, 2020,1: 1176-1187.
[14]Kapoor I, Bodo J, Hill BT, et al. Targeting BCL-2 in B-cell malignancies and overcoming therapeutic resistance[J].Cell Death Dis, 2020,2: 941-952.
[15]Sarif Z, Tolksdorf B, Fechner H,et al. Mcl-1 targeting strategies unlock the proapoptotic potential of TRAIL in melanoma cells[J]. Mol Carcinog, 2020:1256-1268.
[16]Zhao WH, Huang BT, Zhang JY, et al. Distinct EphB4-mediated mechanisms of apoptotic and resistance to dasatinib in human chronic myeloid leukemia and K562 cell lines[J]. Leuk Res, 2017:28-33.
[17]Shi X, Zhu M, Gong Z,et al.Homoharringtonine suppresses LoVo cell growth by inhibiting EphB4 and the PI3K/AKT and MAPK/EKR1/2 signaling pathways[J].Food Chem Toxicol,2020:110960.doi: 10.1016/j.fct.2019.110960.
[18]Dixon SJ, Lemberg KM, Lamprecht MR, et al.Ferroptosis: an iron-dependent form of nonapoptotic cell death[J].Cell, 2012:1060-1072.
[19]Yang WS, SriRamaratnam R, Welsch ME, et al.Regula-tion of ferroptotic cancer cell death by GPX4[J]. Cell, 2014 Jan 16;317-331.
[20]Bersuker K, Hendricks JM, Li Z, Magtanonget al. The CoQ oxidoreductase FSP1 acts parallel to GPX4 to inhibit ferroptosis[J].Nature,2019:688-692.
[21]Kraft VAN, Bezjian CT, Pfeiffer S,et al. GTP Cyclohy-drolase 1/tetrahydrobiopterin counteract ferroptosis through lipid remodeling[J].ACS Cent Sci, 2020,22:41-53.
[22]Li W, Luo LX, Zhou QQ,et al. Phospholipid peroxidation inhibits autophagy via stimulating the delipidation of oxidized LC3-PE[J]. Redox Biol,2022, 5,102421. doi: 10.1016/j.redox.2022.102421.
[23]Pollak N,Lindner A,Imig D,et al.Cell cycle progression and transmitotic apoptosis resistance promote escape from extrinsic apoptosis[J].Cell Sci, 2021,15: 1-15.
[24]Lin L, Ding D, Xiao X, et al.Ametinib potentiates TRAIL-induced apoptosis via FBW7-dependent Mcl-1 degradation in colorectal cancer cells[J]. Cell Mol Med,2020,24: 6822-6832.
[25]Yoon JY, Woo SM, Seo SU, et al. Autophagy inhibitor, enhances the apoptotic effects of TRAIL through miR-216a-5p-mediated DR5 upregulation and DUB3-mediated Mcl-1 downregulation[J].Int J Mol Sci, 2021,21:17-30.

抗凋亡抑制剂维奈克拉在治疗髓系白血病的研究进展

Research progress of anti-apoptotic inhibitor venetoclax in treatment of myeloid leukemia

PDF

可视化

摘要/Abstract

引用本文

使用本文

参考文献

相关文章 15

编辑推荐

Metrics

本文评价

[1]	闫霖, 陆珏秀, 罗颖, 刘先霞. BM-MSCs来源外泌体介导铁死亡减轻大鼠心肌细胞系H9c2缺氧/复氧损伤[J]. 基础医学与临床, 2023, 43(5): 771-776.
[2]	翟雪莹, 王芳, 余佳. PABPC1对人单核白血病细胞系THP-1翻译活性的影响[J]. 基础医学与临床, 2023, 43(5): 751-754.
[3]	张梦瑶, 牛姝, 蔡静, 赵志刚, 周艳. miR-140-5p靶向HMGB1/IκB-α轴对糖尿病大鼠视网膜病变的影响[J]. 基础医学与临床, 2023, 43(4): 615-620.
[4]	刘月, 曹阳, 顾伟英, 商丽梅, 刘琰. 地西他滨联合三氧化二砷抑制急性髓系白血病细胞系增殖和促进凋亡[J]. 基础医学与临床, 2023, 43(4): 608-614.
[5]	金涛, 杨青山, 吴树金, 朱晓燕, 史宇悰, 牛建雄, 刘林. 内质网应激在骨关节炎中作用的研究进展[J]. 基础医学与临床, 2023, 43(3): 476-480.
[6]	曲大鹏, 孙会艳, 李强, 王洪权. 铁死亡在蛛网膜下腔出血早期脑损伤发病机制中作用的研究进展[J]. 基础医学与临床, 2023, 43(3): 486-489.
[7]	汪博, 张明焕. CIRC_0044235靶向miR-574-5p减轻IL-1β诱导的人软骨细胞损伤[J]. 基础医学与临床, 2023, 43(3): 419-426.
[8]	庞兰, 李佩璠, 郑蕾, 王艺明. 利培酮通过影响Wnt/β-catenin信号通路诱导人成骨细胞系hFob1.19凋亡[J]. 基础医学与临床, 2023, 43(3): 374-379.
[9]	张梦瑶, 牛姝, 蔡静, 张立香, 赵志刚. 丹参酮ⅡA减轻高糖诱导的小鼠足细胞系PMC-5凋亡和氧化应激反应[J]. 基础医学与临床, 2023, 43(2): 277-282.
[10]	王卉, 苏宪, 张赢赢, 褚战亚, 孙朝晖, 张金玲, 张倩倩. 异鼠李素减轻糖尿病视网膜病变大鼠视网膜细胞凋亡[J]. 基础医学与临床, 2023, 43(2): 265-270.
[11]	刘婷婷, 韩超, 赵小玲, 孔为民. 二甲双胍抑制人宫颈鳞癌细胞系SiHa和CaSKi增殖及促进细胞凋亡[J]. 基础医学与临床, 2023, 43(2): 283-288.
[12]	付士祥, 席月, 丁龙坤, 闫曼, 赵俊, 焦玉东, 吴亮. 鲍曼不动杆菌外膜囊泡诱发人单核-巨噬细胞THP-1的炎性反应[J]. 基础医学与临床, 2023, 43(1): 110-115.
[13]	顾炜, 祝剑平, 吴品雯. 丙泊酚减轻低氧诱导的大鼠肾上腺嗜铬细胞瘤细胞系PC12炎性反应和细胞凋亡[J]. 基础医学与临床, 2023, 43(1): 137-143.
[14]	董军立, 蔡少康, 严蕾, 蔡毅. 二甲双胍抑制腰椎间盘退变模型兔椎间盘组织的细胞凋亡[J]. 基础医学与临床, 2023, 43(1): 116-122.
[15]	庄志诚, 官国先. 铁死亡在结直肠癌治疗中的作用[J]. 基础医学与临床, 2023, 43(1): 174-177.